Anti-hypertensives for Cardiac/Circ Problem: 25.8% of denials overturned
In 31 California IMR decisions from 2005 to 2023, reviewers overturned 8 (25.8%). In the last five years: 75.0% of 4. 31 were medical-necessity disputes.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 3 | 66.7% |
| 2023 | 1 | 100.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 8 | 0.0% | 25.8% |
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 6 | 33.3% | 25.8% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 4 | 50.0% | 25.8% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 3 | 0.0% | 25.8% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 3 | 33.3% | 25.8% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for tadalafil 20 mg tablet, three tablets per day. The U.S. Food and Drug Administration (FDA) approves the use of tadalafil for the treatment of pulmonary arterial hypertension. Researchers report that tadalafil shows favorable results on exercise capacity, symptoms, hemodynamics, and time to clinical worsening in patients with …”
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Bystolic 5 mg daily. While beta blockers are not regarded as the optimal first-line therapy for the management of hypertension, they may be indicated in certain clinical situation, especially in conjunction with an angiotensin II receptor blocker (ARB) as in this case, including for patients with rhythm …”
“Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Tyvaso Inhalation Solution (Starter Kit followed by Refill Kit for maintenance).The submitted documentation supports that the requested medication is medically necessary. The development and approval of 14 medications over the last several decades have led to a rapidly evolving approach to therapy for pulmonary arterial hypertension. Tyvaso …”
And one the reviewer upheld
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Edarbyclor (azilsartan-chlorthalidone). The records provided for review document that this patient has been treated with multiple medications for hypertension in the past. Aside from Edarbyclor, there is no report of treatment with any other angiotensin-receptor blocker (ARB) and thiazide combinations. Although the provider reported that Edarbyclor has …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Anti-hypertensives denials for Cardiac/Circ Problem overturned?
In 31 California IMR decisions from 2005 to 2023, reviewers overturned 8 (25.8%). In the last five years: 75.0% of 4. 31 were medical-necessity disputes.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.